About The Study: There were significant increases in human papillomavirus (HPV) vaccine administration among commercially insured adults ages 27 to 45 after the Advisory Committee on Immunization Practices recommended patient-clinician shared decision-making for HPV vaccination for this age group in 2019. Further research is warranted to explore the decision-making process in receiving HPV vaccination and to develop effective decision aids to maximize the cancer prevention benefit in this age group.
Authors: Ryan Suk, Ph.D., M.S., of the University of Texas Health Science Center at Houston School of Public Health, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2022.4716)
